Compare STBA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | STOK |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.0B |
| IPO Year | 1995 | 2019 |
| Metric | STBA | STOK |
|---|---|---|
| Price | $40.58 | $34.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $43.00 | $36.10 |
| AVG Volume (30 Days) | 241.2K | ★ 589.0K |
| Earning Date | 04-23-2026 | 04-15-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | 2.35 | ★ 30.67 |
| EPS | ★ 3.49 | 0.85 |
| Revenue | N/A | ★ $36,555,000.00 |
| Revenue This Year | $10.20 | $428.68 |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | ★ $11.92 | $40.67 |
| Revenue Growth | N/A | ★ 316.34 |
| 52 Week Low | $30.84 | $5.35 |
| 52 Week High | $44.91 | $39.81 |
| Indicator | STBA | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 57.06 |
| Support Level | $37.06 | $30.50 |
| Resistance Level | $44.14 | $35.75 |
| Average True Range (ATR) | 1.37 | 2.31 |
| MACD | -0.41 | -0.01 |
| Stochastic Oscillator | 15.91 | 49.89 |
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.